Results acquired from their mice-based study, showed similarity with the ones obtained from the patients, indicating the therapeutic potentials of IL-38 in the immunopathogenesis of IBD by a reduction in inflammation through the inhibitory effects on p-STAT3 and NF-κB [151]. The gene discussed is NFKB1; the disease is inflammatory bowel disease.